Annual SGA
$103.35 M
+$12.88 M+14.23%
December 31, 2023
Summary
- As of February 7, 2025, DNLI annual SGA is $103.35 million, with the most recent change of +$12.88 million (+14.23%) on December 31, 2023.
- During the last 3 years, DNLI annual SGA has risen by +$43.03 million (+71.33%).
- DNLI annual SGA is now at all-time high.
Performance
DNLI SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$24.95 M
-$245.00 K-0.97%
September 30, 2024
Summary
- As of February 7, 2025, DNLI quarterly SGA is $24.95 million, with the most recent change of -$245.00 thousand (-0.97%) on September 30, 2024.
- Over the past year, DNLI quarterly SGA has dropped by -$245.00 thousand (-0.97%).
- DNLI quarterly SGA is now -8.07% below its all-time high of $27.14 million, reached on March 31, 2023.
Performance
DNLI Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$5.08 B
-$427.49 M-9.20%
September 30, 2024
Summary
- As of February 7, 2025, DNLI TTM SGA is -$5.08 billion, with the most recent change of -$427.49 million (-9.20%) on September 30, 2024.
- Over the past year, DNLI TTM SGA has dropped by -$5.18 billion (-5149.04%).
- DNLI TTM SGA is now -4803.29% below its all-time high of -$103.51 million.
Performance
DNLI TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
DNLI Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +14.2% | -1.0% | -5149.0% |
| 3 y3 years | +71.3% | +6.1% | -5709.8% |
| 5 y5 years | +219.5% | +6.1% | -5709.8% |
DNLI Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +30.7% | -8.1% | +17.9% | -138.9% | at low |
| 5 y | 5-year | at high | +122.4% | -8.1% | +129.3% | -265.3% | at low |
| alltime | all time | at high | +1923.4% | -8.1% | +719.1% | -4803.3% | at low |
Denali Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $24.95 M(-1.0%) | $100.15 M(-0.4%) |
| Jun 2024 | - | $25.19 M(-0.2%) | $100.52 M(-0.9%) |
| Mar 2024 | - | $25.24 M(+1.9%) | $101.45 M(-1.8%) |
| Dec 2023 | $103.35 M(+14.2%) | $24.77 M(-2.2%) | $103.35 M(+1.2%) |
| Sep 2023 | - | $25.32 M(-3.0%) | $102.10 M(+2.1%) |
| Jun 2023 | - | $26.12 M(-3.8%) | $100.03 M(+5.2%) |
| Mar 2023 | - | $27.14 M(+15.4%) | $95.07 M(+5.1%) |
| Dec 2022 | $90.47 M(+14.4%) | $23.52 M(+1.1%) | $90.47 M(+2.0%) |
| Sep 2022 | - | $23.26 M(+9.9%) | $88.72 M(+4.6%) |
| Jun 2022 | - | $21.16 M(-6.1%) | $84.78 M(+2.6%) |
| Mar 2022 | - | $22.54 M(+3.6%) | $82.66 M(+4.6%) |
| Dec 2021 | $79.06 M(+31.1%) | $21.76 M(+12.6%) | $79.06 M(+5.0%) |
| Sep 2021 | - | $19.32 M(+1.4%) | $75.29 M(+4.9%) |
| Jun 2021 | - | $19.05 M(+0.6%) | $71.78 M(+7.6%) |
| Mar 2021 | - | $18.94 M(+5.2%) | $66.71 M(+10.6%) |
| Dec 2020 | $60.33 M | $17.99 M(+13.9%) | $60.33 M(+13.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2020 | - | $15.80 M(+13.1%) | $53.21 M(+9.4%) |
| Jun 2020 | - | $13.97 M(+11.3%) | $48.62 M(-2.2%) |
| Mar 2020 | - | $12.55 M(+15.4%) | $49.73 M(+7.0%) |
| Dec 2019 | $46.48 M(+43.7%) | $10.88 M(-3.0%) | $46.48 M(-0.4%) |
| Sep 2019 | - | $11.21 M(-25.6%) | $46.65 M(+5.4%) |
| Jun 2019 | - | $15.08 M(+61.9%) | $44.27 M(+22.7%) |
| Mar 2019 | - | $9.31 M(-15.7%) | $36.09 M(+11.6%) |
| Dec 2018 | $32.35 M(+106.3%) | $11.04 M(+25.0%) | $32.35 M(+22.7%) |
| Sep 2018 | - | $8.84 M(+28.2%) | $26.37 M(+23.8%) |
| Jun 2018 | - | $6.90 M(+23.8%) | $21.31 M(+18.5%) |
| Mar 2018 | - | $5.57 M(+9.9%) | $17.98 M(+14.6%) |
| Dec 2017 | $15.68 M(+33.7%) | $5.07 M(+34.3%) | $15.68 M(+14.8%) |
| Sep 2017 | - | $3.77 M(+5.9%) | $13.66 M(+38.2%) |
| Jun 2017 | - | $3.56 M(+8.9%) | $9.88 M(+56.4%) |
| Mar 2017 | - | $3.27 M(+7.5%) | $6.32 M(+107.5%) |
| Dec 2016 | $11.73 M(+129.7%) | $3.05 M | $3.05 M |
| Dec 2015 | $5.11 M | - | - |
FAQ
- What is Denali Therapeutics annual SGA?
- What is the all time high annual SGA for Denali Therapeutics?
- What is Denali Therapeutics annual SGA year-on-year change?
- What is Denali Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Denali Therapeutics?
- What is Denali Therapeutics quarterly SGA year-on-year change?
- What is Denali Therapeutics TTM SGA?
- What is the all time high TTM SGA for Denali Therapeutics?
- What is Denali Therapeutics TTM SGA year-on-year change?
What is Denali Therapeutics annual SGA?
The current annual SGA of DNLI is $103.35 M
What is the all time high annual SGA for Denali Therapeutics?
Denali Therapeutics all-time high annual SGA is $103.35 M
What is Denali Therapeutics annual SGA year-on-year change?
Over the past year, DNLI annual SGA has changed by +$12.88 M (+14.23%)
What is Denali Therapeutics quarterly SGA?
The current quarterly SGA of DNLI is $24.95 M
What is the all time high quarterly SGA for Denali Therapeutics?
Denali Therapeutics all-time high quarterly SGA is $27.14 M
What is Denali Therapeutics quarterly SGA year-on-year change?
Over the past year, DNLI quarterly SGA has changed by -$245.00 K (-0.97%)
What is Denali Therapeutics TTM SGA?
The current TTM SGA of DNLI is -$5.08 B
What is the all time high TTM SGA for Denali Therapeutics?
Denali Therapeutics all-time high TTM SGA is -$103.51 M
What is Denali Therapeutics TTM SGA year-on-year change?
Over the past year, DNLI TTM SGA has changed by -$5.18 B (-5149.04%)